Research map: Efficacy of anti-GD2 antibody immunotherapy with filgrastim and teceleukin versus standard treatment with sargramostim, aldesleukin and isotretinoin in children with high-risk neuroblastoma

Back to the article

Papers in this map

  1. Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma · Alice Lin-Tsing Yu · 2010 · 1846 citations · Cited by this paper
  2. Pretreatment serum vitamin D levels predict the therapeutic efficacy of atezolizumab plus bevacizumab therapy in advanced hepatocellular carcinoma: a multicenter analysis · 2026 · Related
  3. GM-CSF: From Growth Factor to Central Mediator of Tissue Inflammation · Burkhard Becher · 2016 · 622 citations · Cited by this paper
  4. Sex differences in the prognostic value of body mass index after curative nephrectomy for high-risk renal cell carcinoma: a multicenter cohort study · 2026 · Related
  5. Evidence for an Age Cutoff Greater Than 365 Days for Neuroblastoma Risk Group Stratification in the Children's Oncology Group · Wendy B. London · 2005 · 597 citations · Cited by this paper
  6. The role of surgical timing in survival of patients with spinal metastases · 2026 · Related
  7. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial · Ruth Lydia Ladenstein · 2018 · 420 citations · Cited by this paper
  8. Racial disparities in time to treatment initiation and survival outcomes in patients with vulvar cancer: a national cancer database analysis · 2026 · Related
  9. M2 Macrophages Phagocytose Rituximab-Opsonized Leukemic Targets More Efficiently than M1 Cells In Vitro · Marzia Leidi · 2009 · 272 citations · Cited by this paper
  10. Real-world clinical outcomes and economic burden of discontinuation of taxane therapy among patients with metastatic castration-resistant prostate cancer · 2026 · Related
  11. Murine Anti-GD2 Monoclonal Antibody 3F8 Combined With Granulocyte-Macrophage Colony-Stimulating Factor and 13-Cis-Retinoic Acid in High-Risk Patients With Stage 4 Neuroblastoma in First Remission · Nai‐Kong V. Cheung · 2012 · 265 citations · Cited by this paper
  12. Clinical utility of comprehensive genomic profiling in thoracic malignancies beyond conventional gene testing · 2026 · Related
  13. Disialoganglioside GD2 on human neuroblastoma cells: target antigen for monoclonal antibody-mediated cytolysis and suppression of tumor growth. · Kalpana Mujoo · 1987 · 248 citations · Cited by this paper
  14. Positive peritoneal cytology and recurrence patterns in endometrial cancer according to postoperative recurrence risk classification: a retrospective cohort study · 2026 · Related
  15. Human granulocyte-macrophage colony-stimulating factor is a growth factor active on a variety of cell types of nonhemopoietic origin. · Shoukat Dedhar · 1988 · 236 citations · Cited by this paper
  16. Prognostic significance of predicted skeletal muscle index after curative-intent resection for non-small cell lung cancer · 2026 · Related
  17. Long-Term Follow-up of a Phase III Study of ch14.18 (Dinutuximab) + Cytokine Immunotherapy in Children with High-Risk Neuroblastoma: COG Study ANBL0032 · Alice Lin-Tsing Yu · 2021 · 224 citations · Cited by this paper
  18. RNF125 mediates the anti-breast cancer activity of betulinic acid through ubiquitin-dependent degradation of MYH9 · 2026 · Related
  19. Phase II Trial of the Anti-GD2Monoclonal Antibody 3F8 and Granulocyte-Macrophage Colony-Stimulating Factor for Neuroblastoma · Brian H. Kushner · 2001 · 208 citations · Cited by this paper
  20. GM-CSF Promotes the Immunosuppressive Activity of Glioma-Infiltrating Myeloid Cells through Interleukin-4 Receptor-α · Gary Kohanbash · 2013 · 195 citations · Cited by this paper
  21. GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma · Brian H. Kushner · 1989 · 177 citations · Cited by this paper
  22. Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. · Edward Barker · 1991 · 167 citations · Cited by this paper
  23. Recombinant granulocyte colony-stimulating factor administration to healthy volunteers: induction of immunophenotypically and functionally altered neutrophils via an effect on myeloid progenitor cells · JM Kerst · 1993 · 164 citations · Cited by this paper
  24. Involvement of the high-affinity receptor for IgG (Fc gamma RI; CD64) in enhanced tumor cell cytotoxicity of neutrophils during granulocyte colony-stimulating factor therapy · Thomas Valerius · 1993 · 129 citations · Cited by this paper
  25. Activation of Peripheral-Blood Granulocytes Is Strongly Correlated With Patient Outcome After Immunotherapy With Anti-GD2 Monoclonal Antibody and Granulocyte-Macrophage Colony-Stimulating Factor · Irene Y. Cheung · 2011 · 71 citations · Cited by this paper
  26. Cancer and Immune Response: Old and New Evidence for Future Challenges · Luis de la Cruz‐Merino · 2008 · 62 citations · Cited by this paper
  27. Pharmacokinetics and pharmacodynamics of ch14.18/CHO in relapsed/refractory high-risk neuroblastoma patients treated by long-term infusion in combination with IL-2 · Nikolai Siebert · 2016 · 58 citations · Cited by this paper
  28. In vitro killing of neuroblastoma cells by neutrophils derived from granulocyte colony-stimulating factor-treated cancer patients using an anti-disialoganglioside/anti-Fc gamma RI bispecific antibody · J Michon · 1995 · 47 citations · Cited by this paper
  29. Phase II Multicenter Trial of Maintenance Biotherapy After Induction Concurrent Biochemotherapy for Patients With Metastatic Melanoma · Steven J O'Day · 2009 · 46 citations · Cited by this paper
  30. Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastoma · Ami Vijay Desai · 2014 · 43 citations · Cited by this paper
  31. G-CSF-Stimulated PMN in Immunotherapy of Breast Cancer with a Bispecific Antibody to FcγRI and to HER-2/neu (MDX-210) · Roland Repp · 1995 · 40 citations · Cited by this paper
  32. Enhanced killing of B lymphoma cells by granulocyte colony‐stimulating factor‐primed effector cells and Hu1D10 – a humanized human leucocyte antigen DR antibody · Bernhard Stockmeyer · 2002 · 38 citations · Cited by this paper
  33. Neutrophils are cytotoxic and growth-inhibiting for neuroblastoma cells with an anti-GD2 antibody but, without cytotoxicity, can be growth-stimulating · Rong‐Long Chen · 2000 · 35 citations · Cited by this paper
  34. Distinct clinical and laboratory activity of two recombinant interleukin-2 preparations. · Jaquelyn A. Hank · 1999 · 29 citations · Cited by this paper
  35. Comparative pharmacokinetics, safety, and tolerability of two sources of ch14.18 in pediatric patients with high-risk neuroblastoma following myeloablative therapy · Araz Marachelian · 2016 · 23 citations · Cited by this paper
  36. Impact of HACA on Immunomodulation and Treatment Toxicity Following ch14.18/CHO Long-Term Infusion with Interleukin-2: Results from a SIOPEN Phase 2 Trial · Nikolai Siebert · 2018 · 22 citations · Cited by this paper
  37. A Phase I/IIa Study of Antidisialoganglioside Antibody Dinutuximab in Japanese Patients With Neuroblastoma · Junichi Hara · 2019 · 9 citations · Cited by this paper
  38. Response to: Correspondence on "G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment" by Mora et al · Paula Martínez-Sanz · 2021 · 2 citations · Cited by this paper
  39. Untitled · Cited by this paper

Source: OpenAlex (CC0)